|
Feb 18
|
|
$244.99
$244.99
+0.0%
|
N/A
|
Finnhub News
|
— |
Finnhub - JNJ
Firm-Record Nine Dean Omar Branham Shirley At...
|
|
Feb 18
|
|
$244.99
$244.99
+0.0%
|
N/A
|
Finnhub News
|
— |
Finnhub - JNJ
Sector Update: Health Care Stocks Decline Lat...
|
|
Feb 18
|
|
$244.99
$244.99
+0.0%
|
N/A
|
Finnhub News
|
— |
Finnhub - JNJ
Johnson & Johnson Balances Oncology Breakthro...
|
|
Feb 18
|
|
$244.99
$244.99
+0.0%
|
N/A
|
Finnhub News
|
— |
Finnhub - JNJ
Halozyme's Q4 Earnings Miss, Higher Royalties...
|
|
Feb 18
|
|
$244.99
$244.99
+0.0%
|
N/A
|
Finnhub News
|
— |
Finnhub - JNJ
Johnson & Johnson to Invest More Than $1 Bill...
|
|
Feb 18
|
|
$244.99
$244.99
+0.0%
|
N/A
|
Finnhub News
|
— |
Finnhub - JNJ
J&J to invest $1 billion in new Pennsylvania ...
|
|
Feb 18
|
|
$244.99
$244.99
+0.0%
|
N/A
|
Finnhub News
|
— |
Finnhub - JNJ
Johnson & Johnson Expands U.S. Footprint with...
|
|
Feb 18
|
|
$244.99
$244.99
+0.0%
|
N/A
|
Finnhub News
|
— |
Finnhub - JNJ
Verizon vs Johnson & Johnson: Which Dividend ...
|
|
Feb 18
|
|
$244.99
$244.99
+0.0%
|
N/A
|
Finnhub News
|
— |
Finnhub - JNJ
Johnson & Johnson (JNJ) Is a Trending Stock: ...
|
|
Feb 18
|
|
$244.99
$244.99
+0.0%
|
N/A
|
Finnhub News
|
— |
Finnhub - JNJ
Is Kenvue (KVUE) Attractively Priced After Sp...
|
|
Feb 18
|
|
$244.99
$244.99
+0.0%
|
N/A
|
Finnhub News
|
— |
Finnhub - JNJ
XLV is A $41 Billion Defensive Healthcare Pla...
|
|
Feb 18
|
|
$244.99
$244.99
+0.0%
|
N/A
|
Finnhub News
|
— |
Finnhub - JNJ
Johnson & Johnson Announce Breakthrough Thera...
|
|
Feb 18
|
|
$244.99
$244.99
+0.0%
|
N/A
|
Finnhub News
|
— |
Finnhub - JNJ
Trellus Health Extends Johnson & Johnson Coll...
|
|
Feb 18
|
|
$244.99
$244.99
+0.0%
|
N/A
|
Finnhub News
|
— |
Finnhub - JNJ
This State Has More Millionaires Per Capita T...
|
|
Feb 17
|
|
$243.33
$244.99
+0.7%
|
N/A
|
Finnhub News
|
— |
Finnhub - JNJ
Jury: Johnson & Johnson Liabile in Case Linki...
|
|
Feb 17
|
|
$243.33
$244.99
+0.7%
|
N/A
|
Finnhub News
|
— |
Finnhub - JNJ
Neumora Therapeutics Stock Jumps, Analyst See...
|
|
Feb 17
|
|
$243.33
$244.99
+0.7%
|
N/A
|
Finnhub News
|
— |
Finnhub - JNJ
Beat the Market the Zacks Way: Micron Technol...
|
|
Feb 17
|
|
$243.33
$244.99
+0.7%
|
N/A
|
Finnhub News
|
— |
Finnhub - JNJ
AbbVie Down Since Q4 Earnings Report: How to ...
|
|
Feb 17
|
|
$243.33
$244.99
+0.7%
|
N/A
|
Finnhub News
|
— |
Finnhub - JNJ
Behind the Scenes of Johnson & Johnson's Late...
|
|
Feb 17
|
|
$243.33
$244.99
+0.7%
|
N/A
|
Finnhub News
|
— |
Finnhub - JNJ
FDA approves RYBREVANT FASPRO™ (amivantamab a...
|
|
Feb 17
|
|
$243.33
$244.99
+0.7%
|
N/A
|
Finnhub News
|
— |
Finnhub - JNJ
Johnson & Johnson's New FDA Approval Lets Lun...
|
|
Feb 16
|
|
$243.45
$244.99
+0.6%
|
N/A
|
Finnhub News
|
— |
Finnhub - JNJ
Johnson And Johnson Talc Verdict Puts Legal R...
|
|
Feb 16
|
|
$243.45
$244.99
+0.6%
|
N/A
|
Finnhub News
|
— |
Finnhub - JNJ
What to Expect From These Drug/Biotech Player...
|
|
Feb 16
|
|
$243.45
$244.99
+0.6%
|
N/A
|
Finnhub News
|
— |
Finnhub - JNJ
J&J's MedTech Shows Strong Growth in 2025: Wi...
|
|
Feb 14
|
|
$243.45
$244.99
+0.6%
|
LONG
|
Finnhub News
|
Jim Cramer expresses a very positive view on Johnson & Johnson. |
Finnhub - JNJ
Johnson & Johnson (JNJ) Is Amazing, Says Jim ...
|
|
Feb 13
|
|
$243.45
$244.99
+0.6%
|
NEUTRAL
|
Finnhub News
|
Johnson & Johnson is dealing with both legal challenges and positive cardiac data that supports its valuation. |
Finnhub - JNJ
Johnson And Johnson Faces Legal Risks While C...
|
|
Feb 13
|
|
$243.45
$244.99
+0.6%
|
N/A
|
Finnhub News
|
— |
Finnhub - JNJ
Pennsylvania jury finds Johnson & Johnson lia...
|
|
Feb 13
|
|
$243.45
$244.99
+0.6%
|
SHORT
|
Finnhub News
|
A Pennsylvania jury determined Johnson & Johnson was liable for a woman's ovarian cancer, according to a plaintiffs' attorney. |
Finnhub - JNJ
Pennsylvania Jury Finds Johnson & Johnson Lia...
|
|
Feb 13
|
|
$243.45
$244.99
+0.6%
|
N/A
|
Finnhub News
|
— |
Finnhub - JNJ
Johnson & Johnson (JNJ) Reports 100% Success ...
|
|
Feb 13
|
|
$243.45
$244.99
+0.6%
|
N/A
|
Finnhub News
|
— |
Finnhub - JNJ
Why is Johnson & Johnson (JNJ) One of the Bes...
|
|
Feb 13
|
|
$243.45
$244.99
+0.6%
|
N/A
|
Finnhub News
|
— |
Finnhub - JNJ
H.C. Wainwright Bullish on Genmab A/S (GMAB)...
|
|
Feb 12
|
|
$244.55
$244.99
+0.2%
|
N/A
|
Finnhub News
|
— |
Finnhub - JNJ
Pentair Just Paid Out: Is This Industrial Div...
|
|
Feb 12
|
|
$244.55
$244.99
+0.2%
|
N/A
|
Finnhub News
|
— |
Finnhub - JNJ
Abbott Labs Just Extended Its Dividend Aristo...
|
|
Feb 12
|
|
$244.55
$244.99
+0.2%
|
N/A
|
Finnhub News
|
— |
Finnhub - JNJ
enGene CEO Talks Detalimogene for Community U...
|
|
Feb 12
|
|
$244.55
$244.99
+0.2%
|
N/A
|
Finnhub News
|
— |
Finnhub - JNJ
Johnson And Johnson Cardiac Data Fuels Fresh ...
|
|
Feb 11
|
|
$240.86
$244.99
+1.7%
|
N/A
|
Finnhub News
|
— |
Finnhub - JNJ
H.C. Wainwright Raises Protagonist Therapeuti...
|
|
Feb 11
|
|
$240.86
$244.99
+1.7%
|
N/A
|
Finnhub News
|
— |
Finnhub - JNJ
Johnson & Johnson Files For Debt Shelf, Size ...
|
|
Feb 11
|
|
$240.86
$244.99
+1.7%
|
N/A
|
Finnhub News
|
— |
Finnhub - JNJ
Should You Buy ISRG Stock Despite a 13% Fall ...
|
|
Feb 11
|
|
$240.86
$244.99
+1.7%
|
N/A
|
Finnhub News
|
— |
Finnhub - JNJ
NIH Stops Johnson & Johnson's Blood Thinner D...
|
|
Feb 11
|
|
$240.86
$244.99
+1.7%
|
N/A
|
Finnhub News
|
— |
Finnhub - JNJ
Can Pfizer's New & Acquired Drugs Offset Its ...
|
|
Feb 11
|
|
$240.86
$244.99
+1.7%
|
N/A
|
Finnhub News
|
— |
Finnhub - JNJ
Bristol-Myers: Walking Blindfolded To A $30 B...
|
|
Feb 11
|
|
$240.86
$244.99
+1.7%
|
N/A
|
Finnhub News
|
— |
Finnhub - JNJ
[Latest] Global Cell Therapy Raw Materials Ma...
|
|
Feb 11
|
|
$240.86
$244.99
+1.7%
|
N/A
|
Finnhub News
|
— |
Finnhub - JNJ
How Recent Analyst Shifts Are Rewriting The S...
|